Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer : a post hoc analysis of the MOSAIC trial
Auclin, Edouard (Bourgogne Franche-Comté University, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France)
André, Thierry (Oncology Multidisciplinary Research Group (GERCOR))
Taieb, Julien (UMR-S 1147, INSERM)
Banzi, Maria (Unit of Medical Oncology, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy)
Van Laethem, Jean-Luc (Université Libre de Bruxelles. Department of Gastroenterology and Digestive diseases, Hopital Erasme)
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia)
Hickish, Tamas (Royal Bournemouth General Hospital (Dorset, Regne Unit))
de Gramont, Aimery (Institut Hospitalier Franco-Britannique. Department of Oncology)
Vernerey, Dewi (Oncology Multidisciplinary Research Group (GERCOR))
Universitat Autònoma de Barcelona

Data:	2019
Resum:	Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2. 35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment. Prognostic and predictive values of post-operative CEA in patients with stage II CC were evaluated with Kaplan-Meier survival curves and Cox model with interaction terms. Disease-free survival (DFS) and overall survival (OS) were estimated. Among 899 stage II CC patients, post-operative CEA was available in 867 (96. 4%); and 434 (48. 65%) had a high-risk stage II disease. The 3-year DFS rate was 88. 5% and 78. 7% in the ≤ 2. 35 ng/mL and > 2. 35 ng/mL group, respectively (P = 0. 006). Use of oxaliplatin showed survival benefit only in patients with high-risk stage II CC and post-operative CEA > 2. 35 ng/ml (interaction term P = 0. 09 and 0. 03 for DFS and OS). CEA is a strong prognostic factor for DFS and OS in stage II CC. In the MOSAIC trial, only high-risk stage II CC patients with post-operative CEA > 2. 35 ng/mL benefited from the addition of oxaliplatin to LV5FU2. NCT00275210 (January 11, 2006).
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Colorectal cancer ; Colon cancer
Publicat a:	British Journal of Cancer, Vol. 121 (july 2019) , p. 312-317, ISSN 1532-1827

DOI: 10.1038/s41416-019-0521-7
PMID: 31296923

6 p, 754.7 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats